Why is there no single unit conversion for tirzepatide?
Compounded tirzepatide is prepared in liquid form, measured in milligrams per milliliter (mg/mL). Your prescription may specify a concentration of 5 mg/mL, 10 mg/mL, or another value depending on your dose protocol and what your compounding pharmacy prepares. That concentration variable is what makes the unit conversion different for every prescription.
When people ask about “units,” they are typically referring to the markings on an insulin syringe. Insulin syringes calibrated to U-100 insulin are often used for subcutaneous peptide injections because of their fine-gauge needles and small volume capacity. On a U-100 syringe, 1 unit equals 0.01 mL. That means 100 units = 1 mL.
The conversion math: two common concentrations
Here is the arithmetic for the two concentrations most commonly discussed, applied to the 7.5 mg dose:
| Concentration | Volume for 7.5 mg | Units (U-100 syringe) |
|---|---|---|
| 5 mg/mL | 1.5 mL | 150 units |
| 10 mg/mL | 0.75 mL | 75 units |
| 2.5 mg/mL | 3 mL | 300 units (requires multiple draws) |
The formula is: Volume (mL) = Dose (mg) ÷ Concentration (mg/mL). To get units on a U-100 syringe, multiply the volume in mL by 100.
A 1 mL insulin syringe cannot hold 150 units if that would require drawing beyond its capacity. At 5 mg/mL, a 7.5 mg dose requires 1.5 mL — you would need a 2 mL or larger syringe, or two separate draws, for that concentration. This is one reason pharmacies may choose higher concentrations for patients on larger doses.
The same “7.5 mg” can mean 75 units or 150 units depending on the vial — the concentration on your label, not the dose, decides what you draw.
The tirzepatide titration schedule
The 7.5 mg/week dose sits at the midpoint of the SURMOUNT-1 trial’s titration schedule. The approved starting dose for most patients is 2.5 mg/week for the first four weeks, with increases in 2.5 mg steps every four weeks as tolerated:
- Weeks 1–4: 2.5 mg/week
- Weeks 5–8: 5 mg/week
- Weeks 9–12: 7.5 mg/week
- Weeks 13–16: 10 mg/week (if tolerated)
- Weeks 17–20: 12.5 mg/week (if tolerated)
- Weeks 21+: 15 mg/week maintenance (if tolerated)
Not all patients reach 15 mg. The maintenance dose is the highest dose that provides the intended effect with acceptable tolerability. Many patients find their optimal maintenance dose at 7.5 mg, 10 mg, or 12.5 mg rather than the maximum. Your clinician makes that determination, not the titration schedule.
Why is the prescription label the only reliable source for your tirzepatide dose?
Compounded tirzepatide prescriptions vary. Your pharmacy may prepare the medication at a different concentration than a chart you found online. The label on your vial will state the concentration — read it before every draw.
Common errors in self-dosing include:
- Assuming concentration: Using a conversion table built for 5 mg/mL when your vial is 10 mg/mL produces a 2× overdose.
- Confusing mL and units:Drawing to the “7.5” mark on a mL-scaled syringe is not the same as 7.5 mg if the concentration is not 1 mg/mL.
- Using the wrong syringe type: An insulin syringe and a standard 1 mL syringe may share the same barrel size but have different scale markings.
If there is any ambiguity, call your pharmacy before injecting. The few minutes this takes are well worth the certainty.
Injection technique for subcutaneous tirzepatide
Tirzepatide is administered subcutaneously — into the fat layer beneath the skin, not into muscle. Common injection sites include the abdomen (at least 2 inches from the navel), the upper outer thigh, and the back of the upper arm. Rotate sites to prevent tissue irritation.
The injection is weekly. Consistency on the same day each week is associated with smoother plasma level curves and fewer GI complaints from peak-level spikes. If you need to shift your injection day by a day or two in a given week, this is generally acceptable — ask your clinician for guidance.
Frequently asked questions
How many units is 7.5 mg of tirzepatide?
The answer depends on the concentration of your specific compounded vial. At a common concentration of 5 mg/mL, 7.5 mg equals 1.5 mL drawn in a 1 mL syringe — that is 150 units on an insulin syringe marked in units. At 10 mg/mL, 7.5 mg equals 0.75 mL (75 units). Always verify concentration on your prescription label and confirm the draw volume with your dispensing pharmacy or clinician.
Why do tirzepatide vials come in different concentrations?
Compounding pharmacies prepare tirzepatide in a range of concentrations to suit different dose protocols. A patient on 2.5 mg/week may receive a lower-concentration vial while a patient on 15 mg/week may receive a higher-concentration vial — reducing injection volume. Your clinician and pharmacy determine the appropriate concentration for your protocol.
Are insulin syringe units the same as milligrams?
No. Insulin syringe units refer to volume markings calibrated to 100-unit insulin (U-100) convention, where 1 unit equals 0.01 mL. These are volume-based markings, not mass-based. To convert milligrams to units on an insulin syringe, you must know the mg/mL concentration of your vial.
What is the titration schedule for tirzepatide?
Clinical trials used a four-week titration schedule starting at 2.5 mg/week. Dose increases typically progress in 2.5 mg steps: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Not every patient reaches the maximum dose; the maintenance dose is the highest dose tolerated with acceptable side effects. Your clinician sets and adjusts your titration schedule.
Can I calculate my tirzepatide dose myself using a conversion chart?
Conversion charts can help you understand the math, but dose calculation for compounded peptides should always be verified with your prescribing clinician or pharmacy before injecting. Concentration errors in self-calculation have caused under- and over-dosing. The stakes of a dosing error are real — always confirm with your clinical team.